CSL Biotherapies comments on influenza vaccine paediatric adverse events

CSL Biotherapies is aware of reports of a number of adverse events following influenza vaccination of children. CSL is one of several suppliers of influenza vaccine in Australia.

CSL is urgently investigating these reports in association with the relevant regulatory bodies including the TGA and WA Health.

“As a further precautionary measure and in support of the Commonwealth Chief Medical Officer’s decision advising GPs and immunisation providers to stop giving seasonal influenza vaccine to children under 5 years of age, CSL has taken the action to withhold further distribution of its paediatric influenza vaccine* nationally to reduce the risk of inadvertent administration in this age group” said Dr Darryl Maher, CSL Medical and Research Director.

The company takes the safety and quality of its products seriously and will provide more detailed information as soon as possible.